Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Advanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer

In brief

The purpose of this study is to evaluate the anti-tumor activity of the combination of experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or MRI scans. Additional goals of this study are to look at patient safety, to determine how long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects the study medications may have on each other, and to find out how long patients remain cancer free on this study treatment.

Key facts

Study ID

NCT00387907

Run by

Sanofi

People needed

6

Starts

2006-10-01

Expected to finish

2008-03-01

Last updated by the study team

2016-05-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of breast cancer
• Evidence that cancer has spread beyond its original location or has come back and cannot be removed by surgery
• No more than one prior treatment for advanced disease
• Her2 positive status
• Adequate liver and kidney function
• No remaining severe harmful effects to prior treatments

You may not qualify if…

• Certain heart condition
• Pregnant Women
• History of another cancer except some skin cancers and cervical cancer
• Taking other treatments for your cancer at the time you enter the trial

Where it is running

• Sanofi-Aventis Administrative Office — Malvern, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.